0000000000055692

AUTHOR

Laura Valsecchi

showing 3 related works from this author

Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

2022

Abstract Background In persons living with HIV (PLWH), the burden of non-communicable chronic diseases increased over time, because of aging associated with chronic inflammation, systemic immune activation, and long-term exposure to the combination antiretroviral therapy (ART). Methods To explore the association of chronological age, age at first ART, and exposure to ART with non-communicable chronic diseases, we performed a cross-sectional analysis to evaluate the prevalence of comorbidities in patients enrolled in the SCOLTA Project, stratified by groups of chronological age (50–59 and 60–69 years) and by years of antiretroviral treatment (ART, ≤ 3 or > 3 years). Results In 1394 subjec…

Cross-Sectional StudieMaleART exposureHIVMultimorbidityHIV InfectionsComorbidityOsteoporosis.Noncommunicable DiseaseBone Diseases MetabolicCross-Sectional StudiesInfectious DiseasesAgeAnti-Retroviral AgentsHypertensionHumansOsteoporosisAnti-Retroviral AgentFemaleHIV InfectionNoncommunicable DiseasesAgedHuman
researchProduct

Factors Associated With Weight Gain in People Treated With Dolutegravir.

2020

AbstractBackgroundAn unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens.MethodsAdult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for …

0301 basic medicinemedicine.medical_specialtyWeight gain.HIV metabolic complications030106 microbiologyHIV metabolic complicationTDFEmtricitabineTenofovir alafenamidedolutegravir HIV metabolic complications TAF TDF weight gain.03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAbacavirInternal medicinemedicineMajor Article030212 general & internal medicinebusiness.industryWeight changeLamivudineweight gaindolutegravirInfectious DiseasesAcademicSubjects/MED00290OncologychemistryTAFRilpivirineDolutegravirmedicine.symptombusinessWeight gainmedicine.drugOpen forum infectious diseases
researchProduct

Additional file 1 of Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

2022

Additional file 1: Table S1. Comorbidities by age class (%), comparison with the general Italian population.

researchProduct